Searle achieves DRAP registration for Denosumab biosimilars

MG News | September 01, 2025 at 10:03 AM GMT+05:00

Add Mettisglobal as a Trusted Source on Google

0:00

September 01, 2025 (MLN): The Searle Company Limited (PSX: SEARL) has successfully obtained registration of Denosumab injections 120mg and 60mg (biosimilar drugs) from the Drug Regulatory Authority of Pakistan.

The company, being the product registration holder in Pakistan, has been granted rights under a License Agreement by Mabwell Pharmaceuticals, China (the manufacturer), to market and sell these biosimilar drugs in Pakistan.

Denosumab is a monoclonal antibody to be used for the management of osteoporosis (60mg) and oncology care (120mg), the company's filing on PSX revealed today.

The company is now preparing for the commercial launch of Denosumab injections in Pakistan, marking a significant milestone in expanding its product portfolio.

This development reflects the company’s commitment to enhancing its product offerings and strengthening its business, thereby improving the quality of its earnings and creating greater value for shareholders.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	178,088.35 124.28M	-0.10% -173.99
ALLSHR	107,787.77 268.89M	-0.05% -49.67
KSE30	53,307.12 28.77M	-0.08% -40.55
KMI30	251,882.78 43.56M	0.15% 372.41
KMIALLSHR	69,238.23 168.42M	0.09% 64.37
BKTi	50,841.80 6.73M	-0.44% -222.92
OGTi	35,295.90 2.02M	0.13% 47.48

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	63,315.00	64,810.00 63,035.00	-1650.00 -2.54%
BRENT CRUDE	87.24	88.06 86.40	-1.12 -1.27%
RICHARDS BAY COAL MONTHLY	105.75	0.00 0.00	-1.55 -1.44%
ROTTERDAM COAL MONTHLY	120.00	120.00 120.00	-0.25 -0.21%
USD RBD PALM OLEIN	1,175.00	1,175.00 1,175.00	0.00 0.00%
CRUDE OIL - WTI	81.63	82.24 80.60	-0.98 -1.19%
SUGAR #11 WORLD	14.56	14.75 14.54	-0.21 -1.42%